Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Failure, Chronic | 16 | 2025 | 934 | 2.960 |
Why?
|
| Renal Dialysis | 17 | 2025 | 951 | 2.930 |
Why?
|
| Atrial Fibrillation | 5 | 2025 | 738 | 1.130 |
Why?
|
| Factor Xa Inhibitors | 1 | 2025 | 60 | 0.880 |
Why?
|
| Pyridones | 2 | 2025 | 140 | 0.880 |
Why?
|
| Peritoneal Dialysis | 2 | 2023 | 133 | 0.860 |
Why?
|
| Hip Fractures | 3 | 2020 | 64 | 0.820 |
Why?
|
| Pyrazoles | 2 | 2025 | 349 | 0.780 |
Why?
|
| Kidney Transplantation | 3 | 2024 | 558 | 0.710 |
Why?
|
| Health Facility Closure | 1 | 2021 | 8 | 0.700 |
Why?
|
| Hospitalization | 6 | 2021 | 1950 | 0.660 |
Why?
|
| Graft Rejection | 1 | 2024 | 552 | 0.650 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2022 | 853 | 0.640 |
Why?
|
| Ambulatory Care Facilities | 2 | 2021 | 231 | 0.630 |
Why?
|
| Histamine H2 Antagonists | 1 | 2018 | 59 | 0.550 |
Why?
|
| Hypertension, Pulmonary | 1 | 2021 | 457 | 0.480 |
Why?
|
| Osteoarthritis, Knee | 4 | 2020 | 282 | 0.450 |
Why?
|
| Proton Pump Inhibitors | 1 | 2018 | 326 | 0.440 |
Why?
|
| Aged | 23 | 2025 | 21025 | 0.420 |
Why?
|
| United States | 13 | 2025 | 12072 | 0.420 |
Why?
|
| Retrospective Studies | 14 | 2025 | 17753 | 0.350 |
Why?
|
| Middle Aged | 21 | 2025 | 28601 | 0.340 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 6797 | 0.330 |
Why?
|
| Medicare | 4 | 2022 | 442 | 0.330 |
Why?
|
| Heart-Assist Devices | 4 | 2020 | 1020 | 0.310 |
Why?
|
| Female | 26 | 2025 | 70963 | 0.280 |
Why?
|
| Male | 25 | 2025 | 64957 | 0.270 |
Why?
|
| Anticoagulants | 2 | 2025 | 605 | 0.260 |
Why?
|
| Thromboembolism | 2 | 2025 | 93 | 0.250 |
Why?
|
| Humans | 31 | 2025 | 131163 | 0.240 |
Why?
|
| Transplant Recipients | 2 | 2024 | 235 | 0.220 |
Why?
|
| Cohort Studies | 8 | 2023 | 5063 | 0.210 |
Why?
|
| Forearm | 1 | 2024 | 39 | 0.210 |
Why?
|
| Stroke | 2 | 2025 | 1061 | 0.210 |
Why?
|
| Allografts | 1 | 2024 | 220 | 0.200 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2024 | 86 | 0.200 |
Why?
|
| Travel | 1 | 2023 | 117 | 0.180 |
Why?
|
| Waiting Lists | 1 | 2024 | 253 | 0.180 |
Why?
|
| Pain Threshold | 2 | 2020 | 24 | 0.180 |
Why?
|
| Hemorrhage | 1 | 2025 | 487 | 0.180 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 705 | 0.180 |
Why?
|
| Nephritis, Interstitial | 1 | 2022 | 41 | 0.180 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1490 | 0.180 |
Why?
|
| Prospective Payment System | 1 | 2021 | 17 | 0.170 |
Why?
|
| Patient Care Bundles | 1 | 2021 | 21 | 0.170 |
Why?
|
| Reoperation | 1 | 2024 | 818 | 0.170 |
Why?
|
| Prosthesis Implantation | 2 | 2020 | 152 | 0.170 |
Why?
|
| Heart Failure | 3 | 2019 | 2332 | 0.170 |
Why?
|
| Risk Assessment | 3 | 2019 | 3711 | 0.170 |
Why?
|
| Antirheumatic Agents | 1 | 2023 | 123 | 0.170 |
Why?
|
| Allopurinol | 1 | 2022 | 79 | 0.170 |
Why?
|
| Retinal Diseases | 1 | 2023 | 142 | 0.170 |
Why?
|
| Central Nervous System Sensitization | 1 | 2020 | 1 | 0.160 |
Why?
|
| Hamstring Muscles | 1 | 2020 | 2 | 0.160 |
Why?
|
| Quadriceps Muscle | 1 | 2020 | 16 | 0.160 |
Why?
|
| Patellofemoral Joint | 1 | 2020 | 5 | 0.160 |
Why?
|
| Propensity Score | 1 | 2021 | 271 | 0.160 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 229 | 0.150 |
Why?
|
| Renal Insufficiency | 1 | 2022 | 259 | 0.150 |
Why?
|
| Muscle Contraction | 1 | 2020 | 147 | 0.150 |
Why?
|
| Health Facility Merger | 1 | 2019 | 8 | 0.150 |
Why?
|
| Hospital Mortality | 3 | 2019 | 1064 | 0.150 |
Why?
|
| Incidence | 4 | 2019 | 3360 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 523 | 0.140 |
Why?
|
| Gout | 1 | 2022 | 169 | 0.140 |
Why?
|
| Adult | 11 | 2024 | 31282 | 0.140 |
Why?
|
| Musculoskeletal Pain | 1 | 2018 | 16 | 0.140 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 3829 | 0.140 |
Why?
|
| Reimbursement, Incentive | 1 | 2018 | 48 | 0.140 |
Why?
|
| Social Participation | 1 | 2018 | 13 | 0.140 |
Why?
|
| Warfarin | 1 | 2018 | 121 | 0.130 |
Why?
|
| Environment Design | 1 | 2017 | 16 | 0.130 |
Why?
|
| Mobility Limitation | 1 | 2017 | 31 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 712 | 0.130 |
Why?
|
| Catheter-Related Infections | 1 | 2019 | 146 | 0.120 |
Why?
|
| Affect | 1 | 2018 | 159 | 0.120 |
Why?
|
| Risk Factors | 6 | 2021 | 11074 | 0.120 |
Why?
|
| Graft Survival | 1 | 2018 | 465 | 0.120 |
Why?
|
| Knee Joint | 1 | 2018 | 177 | 0.120 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2018 | 105 | 0.120 |
Why?
|
| Bariatric Surgery | 1 | 2018 | 154 | 0.120 |
Why?
|
| Mortality | 1 | 2018 | 264 | 0.120 |
Why?
|
| Cause of Death | 1 | 2018 | 506 | 0.120 |
Why?
|
| Anemia | 1 | 2020 | 354 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2020 | 442 | 0.120 |
Why?
|
| Perception | 1 | 2017 | 231 | 0.110 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 352 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 464 | 0.110 |
Why?
|
| Sepsis | 1 | 2019 | 493 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2017 | 295 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 546 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2025 | 12936 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2019 | 1345 | 0.100 |
Why?
|
| Age Factors | 1 | 2018 | 2825 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 999 | 0.080 |
Why?
|
| Depression | 1 | 2019 | 1320 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2020 | 3147 | 0.060 |
Why?
|
| Obesity | 1 | 2018 | 2426 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 2121 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 5196 | 0.060 |
Why?
|
| Prognosis | 3 | 2019 | 4886 | 0.060 |
Why?
|
| Arm | 1 | 2024 | 71 | 0.050 |
Why?
|
| Time Factors | 3 | 2018 | 6196 | 0.050 |
Why?
|
| Hydroxychloroquine | 1 | 2023 | 21 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2020 | 3359 | 0.050 |
Why?
|
| Agrochemicals | 1 | 2022 | 13 | 0.050 |
Why?
|
| Paraquat | 1 | 2022 | 14 | 0.050 |
Why?
|
| Cations | 1 | 2022 | 38 | 0.050 |
Why?
|
| Registries | 2 | 2019 | 1634 | 0.040 |
Why?
|
| Gout Suppressants | 1 | 2022 | 75 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2022 | 136 | 0.040 |
Why?
|
| Postsynaptic Potential Summation | 1 | 2020 | 2 | 0.040 |
Why?
|
| Young Adult | 3 | 2019 | 10103 | 0.040 |
Why?
|
| Electromyography | 1 | 2020 | 134 | 0.040 |
Why?
|
| Ownership | 1 | 2019 | 33 | 0.040 |
Why?
|
| Dabigatran | 1 | 2018 | 26 | 0.040 |
Why?
|
| Knee | 1 | 2018 | 21 | 0.040 |
Why?
|
| Rivaroxaban | 1 | 2018 | 49 | 0.030 |
Why?
|
| Anti-Obesity Agents | 1 | 2018 | 47 | 0.030 |
Why?
|
| Iowa | 1 | 2018 | 13 | 0.030 |
Why?
|
| Alabama | 1 | 2018 | 43 | 0.030 |
Why?
|
| Indians, North American | 1 | 2018 | 71 | 0.030 |
Why?
|
| Thiazoles | 1 | 2018 | 113 | 0.030 |
Why?
|
| Radiography | 1 | 2020 | 743 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2019 | 188 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2018 | 276 | 0.030 |
Why?
|
| Renal Replacement Therapy | 1 | 2019 | 172 | 0.030 |
Why?
|
| Hypotension | 1 | 2019 | 187 | 0.030 |
Why?
|
| Pyridines | 1 | 2018 | 255 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2018 | 191 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2018 | 279 | 0.030 |
Why?
|
| Reference Values | 1 | 2018 | 676 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2018 | 6459 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 222 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2018 | 297 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 386 | 0.030 |
Why?
|
| Critical Illness | 1 | 2020 | 630 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1797 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 558 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1483 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 2114 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 554 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 4738 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2018 | 800 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 20987 | 0.020 |
Why?
|
| Mice | 1 | 2022 | 18301 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 33912 | 0.010 |
Why?
|